BTIG Research Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its target price hoisted by BTIG Research from $96.00 to $103.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price target suggests a potential upside of 30.30% from the stock’s current price.

ESTA has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Needham & Company LLC upped their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. TD Cowen raised their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday. Mizuho lifted their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Finally, Citigroup raised their target price on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $96.50.

Establishment Labs Stock Down 13.4%

ESTA stock traded down $12.20 during trading on Thursday, reaching $79.05. 1,034,808 shares of the stock were exchanged, compared to its average volume of 551,048. The firm’s 50 day moving average is $86.17 and its 200 day moving average is $74.15. The firm has a market cap of $2.33 billion, a P/E ratio of -53.05 and a beta of 1.07. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. Establishment Labs has a twelve month low of $33.35 and a twelve month high of $97.59.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. During the same quarter in the prior year, the business earned ($0.57) earnings per share. Establishment Labs’s revenue for the quarter was up 31.7% on a year-over-year basis. As a group, research analysts forecast that Establishment Labs will post -1.07 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Simplify Asset Management Inc. increased its holdings in Establishment Labs by 92.1% during the fourth quarter. Simplify Asset Management Inc. now owns 72,894 shares of the company’s stock worth $5,313,000 after buying an additional 34,946 shares during the last quarter. Sigma Planning Corp boosted its stake in Establishment Labs by 325.5% in the first quarter. Sigma Planning Corp now owns 20,424 shares of the company’s stock valued at $1,160,000 after acquiring an additional 15,624 shares during the last quarter. SG Americas Securities LLC boosted its stake in Establishment Labs by 134.3% in the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company’s stock valued at $2,154,000 after acquiring an additional 21,742 shares during the last quarter. AlTi Global Inc. bought a new position in shares of Establishment Labs during the 1st quarter valued at approximately $842,000. Finally, Union Square Park Capital Management LLC grew its position in shares of Establishment Labs by 16.7% during the 1st quarter. Union Square Park Capital Management LLC now owns 105,000 shares of the company’s stock valued at $5,962,000 after acquiring an additional 15,000 shares during the period. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.